Pharmaceutical company Dr Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE: RDY) on Thursday announced the availability of its antipsychotic medication Fluphenazine Hydrochloride Tablets, USP in the US market.
Fluphenazine Hydrochloride Tablets, USP are a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg and 10 mg, and are approved by the US Food and Drug Administration (FDA).
The Prolixin brand and generic had US sales of approximately USD134m MAT for the 12 months ending in December 2020, according to IQVIA Health.
Fluphenazine is used in the treatment of chronic psychoses such as schizophrenia and psychotic symptoms such as hallucinations, delusions and hostility.
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress